Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130457 | 1.00 | ANPEP (0.48) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL1618810 | 1.00 | ANPEP (0.48) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL172840 | 0.79 | ANPEP (0.44) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL11470552 | 0.78 | HTR2A (0.33) | TDP1 | |
| SCHEMBL171570 | 0.78 | PLA2G1B (0.32) | ANPEPERAP1ERAP2TSHRALDH1A1 | |
| SCHEMBL56311 | 0.75 | ANPEP (0.65) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL3601315 | 0.72 | SLC7A5 (0.45) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL56763 | 0.72 | GMNN (0.63) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL10343746 | 0.72 | ANPEP (0.61) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL7058844 | 0.71 | ANPEP (0.52) | ANPEPERAP1ERAP2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973875-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8609706-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8461191-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461191-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8304428-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-7745464-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. | 2010-06-29 | — | — | US | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| CN-101006065-A | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007075387-A1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | ANPEP 3902/4885ERAP1 1890/4885ERAP2 2566/4885 |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | ANPEP 3834/4885ERAP1 2316/4885ERAP2 2752/4885 |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCL2L1 | ANPEP 4040/4885ERAP1 2520/4885ERAP2 3155/4885 |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | ANPEP 3834/4885ERAP1 2316/4885ERAP2 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.